Business Wire

BEHAVOX

18.5.2022 15:51:04 CEST | Business Wire | Pressemeddelelse

Del
Behavox-forskning i kontinuerlig læring med på International Conference on Acoustics, Speech and Signal Processing (ICASSP)

Behavox , som udbyder en række sikkerhedsprodukter, der hjælper compliance-, HR- og sikkerhedsafdelingerne med at beskytte deres virksomhed og kolleger mod ondsindede aktører, fortæller i dag, at dens akademiske forskningsdokument om kunstig intelligens "kontinuerlig læring med lattice-fri MMI til stemmegenkendelse" er blevet accepteret af International Conference on Acoustics, Speech, and Signal Processing (ICASSP). ICASSP er verdens største og mest omfattende tekniske konference med fokus på signalbehandling og tilhørende anvendelse. Behavox præsenterede den 9. maj 2022 dette dokument i Singapore for IEEE ICASSP 2022 .

"Nogle gange forsker videnskabsfolk for videnskabens skyld, og samfundet oplever ikke nogen umiddelbare fordele af forskningen. Vi har derimod skubbet videnskaben til en ny grænse for at finde en løsning på et aktuelt problem," siger Behavox's CTO Joseph Benjamin. "Vi er beærede over at have modtaget anerkendelse fra en så prestigefyldt konference og er meget stolte af vores team og det arbejde, folkene har udført."

Dokumentet, der er forfattet af Behavox's maskinlæringsteam, ser på udfordringerne i forbindelse med løbende forbedring af stemmegenkendelsessystemer i miljøer, der kræver beskyttelse af personoplysninger. Vores forskning har direkte forbindelse til Behavox's FoU-tilgang, der giver kunderne den bedste transskriptionskvalitet på det finansielle marked. I FinTech sker der hele tiden ændringer i det sprog og de data, som Behavox-systemerne hurtigt og pålideligt skal behandle, og stigningen i kryptovalutaer og videokommunikation er blot to eksempler.

Derfor skal maskinlæringsmodeller jævnligt opdateres med relevante data. For at gøre sådanne opdateringer mulige, uden at sætte databeskyttelsen over styr, skal modellen gradvist kunne forbedres i sikre klientmiljøer uden adgang til historiske data og data fra andre kunder. Dette er en alvorlig udfordring inden for maskinlæring på grund af den katastrofale glemsomhed, hvor modellen, efter at have forbedret en bestemt type data, begynder at præstere dårligt på tidligere lærte data.

ICASSP-dokumentet fra Behavox bidrager til den fortsatte læring til brug ved stemmegenkendelse. Forfatterne foreslår en ny algoritme, der udvider og forfiner den almindeligt anvendte LWF-teknik (Learning Without Forgetting), der er afhængig af en regulariseringsterm og tvinger neurale netværk til at mindske glemsomhed. Mere specifikt designede forfatterne en nyhed i form af neurale netværk med indlæring af tab på sekvensniveau, der kan bruges i stedet for den konventionelle, punktvise LWF. De viste en betydelig reduktion i glemsomhed, når man finjusterede det neurale netværk sekventielt efter forskellige accenter- og taleformer.

Behavox har konstateret, at brugen af stemmeplatforme med årene er steget 94 procent, og at næsten en tredjedel af al kommunikation på arbejdspladsen i gennemsnit foregår som telefonmøder eller videokonferencer.

Denne teknik er allerede blevet anvendt med succes på dets danske system, hvor samarbejdet mellem Behavox's lingvister, maskinlæringsteamet og en kunde gav Behavox mulighed for at opbygge sit første danske transskriptionssystem, der arbejder pålideligt med bankdata.

Om Behavox

Behovox udbyder en række sikkerhedsprodukter, der hjælper compliance-, HR- og sikkerhedsafdelingerne med at beskytte deres virksomhed og kolleger mod ondsindede aktører.

Med AI-baseret analyse af alle virksomhedens kommunikationsdata, herunder e-mail, chat, telefonmøde- og videokonferenceplatforme, hjælper Behavox virksomhederne med at identificere ulovlig, umoralsk og skadelig adfærd på arbejdspladsen.

Behavox, der blev grundlagt i 2014, har hovedkvarter i Montreal og kontorer i New York, London, Seattle, Singapore og Tokyo.

Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.

Link:

ClickThru

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release

In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye